Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Velpatasvir intermediate, preparation method thereof and preparation of Velpatasvir

A time and protective gas technology, applied in the field of velpatasvir intermediates, can solve problems such as being unsuitable for industrial production, poor chiral purity of products, and difficulty in controlling chiral isomers

Active Publication Date: 2018-02-09
SHANGHAI BOCIMED PHARMA CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to overcome the preparation method of Velpatasvir (Velpatasvir or GS5816) in the prior art, the control of chiral isomers in the reaction process is difficult, the obtained product has poor chiral purity, and cannot reach the raw material Drug standard, low total yield, high production cost, not suitable for industrial production and other defects, but provides velpatasvir intermediates, preparation methods and preparation methods of velpatasvir

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Velpatasvir intermediate, preparation method thereof and preparation of Velpatasvir
  • Velpatasvir intermediate, preparation method thereof and preparation of Velpatasvir
  • Velpatasvir intermediate, preparation method thereof and preparation of Velpatasvir

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0141] Example 1: Preparation of compound 10 (L is Br, P is tert-butoxycarbonyl, namely Boc)

[0142]

[0143] Compound 11 (2kg, 3.18mol, 1eq) was dissolved in methanol, and a mass concentration of 37% concentrated hydrochloric acid (1.33L, 5eq) was added (the mass concentration refers to the percentage of the mass of hydrogen chloride in the total mass of the hydrochloric acid solution), heated Reflux (60°C~65°C), react for 2-6 hours, TLC shows complete reaction, drop to room temperature, add methyl tert-butyl ether slowly, after the dropwise addition, stir at 0-10°C for 2-5 hours, filter , the solid was suspended in dichloromethane, saturated sodium bicarbonate was added, stirred for 1 hour, filtered, the organic phase was washed with water and saturated sodium chloride successively, concentrated to dryness, and 1.52kg of compound 10 was obtained, the yield was 90.0%, and the HPLC purity was 98.23% .

Embodiment 2

[0144] The preparation of embodiment 2 compound 14 (P is Boc)

[0145]

[0146] Compound 25 (1.96kg, 5.29mol, 1.0eq) and compound 24 (1.37kg, 1.05eq) were dissolved in N, N-dimethylformamide (DMF), potassium carbonate (730.8g, 1.05eq) was added, nitrogen Vacuum replaced three times, heated to 20-40°C and stirred for 3 hours. TLC showed complete reaction of compound 25. Reduce to 5-10°C, add water dropwise, stir at 5-10°C for 2-3 hours, filter, wash the filter cake with water, and dry to obtain 2.85kg of compound 14 with a yield of 98.0% and an HPLC purity of 98.56%.

Embodiment 3

[0147] Preparation of Example 3 Compound 13 (P is Boc, i.e. tert-butoxycarbonyl)

[0148]

[0149] Compound 14 (2.85kg, 5.18mol, 1eq) was dissolved in isopropyl acetate, added isopropyl acetate / hydrogen chloride (1.33L, 5eq), heated to reflux (60°C-65°C), reacted for 2-6 hours, TLC Show complete reaction, lower to room temperature, slowly add methyl tert-butyl ether dropwise, stir at 0-10°C for 2-5 hours after dropwise addition, filter, suspend the solid in dichloromethane, add saturated sodium bicarbonate, stir After filtering for 1 hour, the organic phase was washed with water and saturated sodium chloride successively, and concentrated to dryness to obtain 2.21 kg of compound 13 with a yield of 95.0% and a purity of 98.86% by HPLC.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a Velpatasvir intermediate, a preparation method thereof and a preparation of Velpatasvir. The invention provides a preparation method of a Velpatasvir intermediate compound 6,which comprises the the step: performing a reaction of nucleophilic substitution on a compound 8 and a compound 7 in an organic solvent under a condition that alkali exists under the protection of protective gas, so as to obtain the compound 6. The preparation method provided by the invention is mild in reaction conditions and simple and safe in operation and does not need special purification equipment, column chromatography isolation operation in an aftertreatment process is avoided, and a chiral isomer is controlled easily; and the yield is high, the chemical and optical purity of Velpatasvir 1 prepared from the intermediate compound 6 are greater than 99.50%, and all impurities are less than 0.10%, so that the Velpatasvir 1 can reach the crude drug standard, is low in cost and is suitable for industrial production.

Description

technical field [0001] The invention relates to a velpatasvir intermediate, a preparation method and a preparation method of velpatasvir. Background technique [0002] In June 2016, the FDA approved another blockbuster anti-hepatitis C drug from Gilead Sciences, Epclusa (Sofosbuvir 400mg+Velpatasvir 100mg), the first anti-hepatitis C drug for the treatment of major genotypes 1-6. Known as the third-generation anti-hepatitis C blockbuster drug after Sofosbuvir and Harvoni. [0003] In October 2016, Gilead Sciences announced the results of 4 global phase III clinical studies, Sofosbuvir, Velpatasvir (Velpatasvir or GS5816) and Voxilaprevir three-in-one tablet cured patients with genotype 1-6 HCV infection The effect is remarkable. The new anti-hepatitis C drug with Velpatasvir as a compound was approved by the FDA in July 2017. The drug name is Vosevi. Vosevi will soon become a star drug in the field of anti-hepatitis C, with a broad market prospect. [0004] The US20150361...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D405/14C07D405/12C07D491/052C07D207/16C07K5/072C07K1/02
CPCC07D491/052Y02P20/55
Inventor 应述欢皮红军公绪栋于冲冲
Owner SHANGHAI BOCIMED PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com